Securities Code: 002294
Securities Abbreviation: Sanofi-Aventis
Number: 2026-064
Shenzhen Sanofi-Aventis Pharmaceutical Co., Ltd.
Announcement on Acceptance of SAL012 Drug Clinical Trial Application
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.
Recently, Shenzhen Sanofi-Aventis Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), its wholly-owned subsidiary Sanofi-Aventis (Chengdu) Biotechnology Co., Ltd., and Sanofi-Aventis (Suzhou) Pharmaceutical Co., Ltd. received acceptance letters from the National Medical Products Administration. The clinical trial application for the Company's independently developed innovative drug "Injection SAL012" (Project Code: SAL012) has been accepted. The relevant information is hereby announced as follows: